FDA Promises No More IND Disruptions Without “Very Valid Reasons,” Nears Agreement With NCI
In Brief: Recompetition Of Frederick Contract Flops, As Others Leave The Field To Litton-Bionetics
Search Committee Finishes Job, Submits Choices To Califano
New ACS Grants to Fund ‘Critical, Urgent’ Research
Sacharin Issue Splits Scientists; ACS Proposes Delaney Changes
UICC Announces Grant Programs to Continue
NCI Goofs On Contract Notice, Won’t Change Improper Deadline
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- Did Vinay Prasad need to mention the Nazis to make a point on the U.S. pandemic response?
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies - Prasad: FDA has confused merely approving drugs with making the world a better place